FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2159841299> ?p ?o ?g. }

• W2159841299 endingPage "1001.e6" @default.
• W2159841299 startingPage "992" @default.
• W2159841299 abstract "Objective To evaluate the safety of pegaptanib sodium injection, a specific vascular endothelial growth factor (VEGF) antagonist, in the treatment of neovascular age-related macular degeneration (AMD) during 2 years of therapy. Design Two concurrent, prospective, randomized, multicenter, double-masked, sham-controlled studies. Methods Patients with all angiographic choroidal neovascularization lesion compositions of AMD received either intravitreous pegaptanib sodium (0.3 mg, 1 mg, 3 mg) or sham injections every 6 weeks for 54 weeks. Those initially assigned to pegaptanib were re-randomized (1:1) to continue or discontinue therapy for 48 more weeks; sham-treated patients were re-randomized (1:1:1:1:1) to continue sham, discontinue, or receive one of the pegaptanib doses. Main Outcome Measures All reported adverse events, serious adverse events, and deaths. Participants In year 1, 1190 subjects received at least one study treatment (0.3 mg, n = 295; 1 mg, n = 301; 3 mg, n = 296; sham, n = 298); 7545 intravitreous injections of pegaptanib were administered. In year 2, 425 subjects (0.3 mg, n = 128; 1 mg, n = 126; 3 mg, n = 120; sham, n = 51) continued the same masked treatment as in year 1 and received at least one study treatment in year 2; 2663 intravitreous injections of pegaptanib were administered in these subjects. Results All doses of pegaptanib were well tolerated. The most common ocular adverse events were transient, mild to moderate in intensity, and attributed to the injection preparation and procedure. There was no evidence of an increase in deaths, in events associated with systemic VEGF inhibition (e.g., hypertension, thromboembolic events, serious hemorrhagic events), or in severe ocular inflammation, cataract progression, or glaucoma in pegaptanib-treated patients relative to sham-treated patients. In year 1, serious injection-related complications included endophthalmitis (12 events, 0.16%/injection), retinal detachment (RD) (6 events [4 rhegmatogenous, 2 exudative], 0.08%/injection), and traumatic cataract (5 events, 0.07%/injection). Most cases of endophthalmitis followed violations of the injection preparation protocol. In patients receiving pegaptanib for >1 year, there were no reports of endophthalmitis or traumatic cataract in year 2; RD was reported in 4 patients (all rhegmatogenous, 0.15%/injection). Conclusion The 2-year safety profile of pegaptanib sodium is favorable in patients with exudative AMD. To evaluate the safety of pegaptanib sodium injection, a specific vascular endothelial growth factor (VEGF) antagonist, in the treatment of neovascular age-related macular degeneration (AMD) during 2 years of therapy. Two concurrent, prospective, randomized, multicenter, double-masked, sham-controlled studies. Patients with all angiographic choroidal neovascularization lesion compositions of AMD received either intravitreous pegaptanib sodium (0.3 mg, 1 mg, 3 mg) or sham injections every 6 weeks for 54 weeks. Those initially assigned to pegaptanib were re-randomized (1:1) to continue or discontinue therapy for 48 more weeks; sham-treated patients were re-randomized (1:1:1:1:1) to continue sham, discontinue, or receive one of the pegaptanib doses. All reported adverse events, serious adverse events, and deaths. In year 1, 1190 subjects received at least one study treatment (0.3 mg, n = 295; 1 mg, n = 301; 3 mg, n = 296; sham, n = 298); 7545 intravitreous injections of pegaptanib were administered. In year 2, 425 subjects (0.3 mg, n = 128; 1 mg, n = 126; 3 mg, n = 120; sham, n = 51) continued the same masked treatment as in year 1 and received at least one study treatment in year 2; 2663 intravitreous injections of pegaptanib were administered in these subjects. All doses of pegaptanib were well tolerated. The most common ocular adverse events were transient, mild to moderate in intensity, and attributed to the injection preparation and procedure. There was no evidence of an increase in deaths, in events associated with systemic VEGF inhibition (e.g., hypertension, thromboembolic events, serious hemorrhagic events), or in severe ocular inflammation, cataract progression, or glaucoma in pegaptanib-treated patients relative to sham-treated patients. In year 1, serious injection-related complications included endophthalmitis (12 events, 0.16%/injection), retinal detachment (RD) (6 events [4 rhegmatogenous, 2 exudative], 0.08%/injection), and traumatic cataract (5 events, 0.07%/injection). Most cases of endophthalmitis followed violations of the injection preparation protocol. In patients receiving pegaptanib for >1 year, there were no reports of endophthalmitis or traumatic cataract in year 2; RD was reported in 4 patients (all rhegmatogenous, 0.15%/injection). The 2-year safety profile of pegaptanib sodium is favorable in patients with exudative AMD." @default.
• W2159841299 created "2016-06-24" @default.
• W2159841299 creator A5019280205 @default.
• W2159841299 date "2006-06-01" @default.
• W2159841299 modified "2023-10-16" @default.
• W2159841299 title "Pegaptanib Sodium for Neovascular Age-Related Macular Degeneration" @default.
• W2159841299 cites W109974915 @default.
• W2159841299 cites W1601975653 @default.
• W2159841299 cites W1789824814 @default.
• W2159841299 cites W1802218256 @default.
• W2159841299 cites W1997324775 @default.
• W2159841299 cites W2004643661 @default.
• W2159841299 cites W2012852444 @default.
• W2159841299 cites W2035353185 @default.
• W2159841299 cites W2037623358 @default.
• W2159841299 cites W2059265707 @default.
• W2159841299 cites W2075086348 @default.
• W2159841299 cites W2075634939 @default.
• W2159841299 cites W2094739999 @default.
• W2159841299 cites W2098155102 @default.
• W2159841299 cites W2100785570 @default.
• W2159841299 cites W2114159573 @default.
• W2159841299 cites W2137893922 @default.
• W2159841299 cites W2156575195 @default.
• W2159841299 cites W2157769714 @default.
• W2159841299 cites W2324588265 @default.
• W2159841299 cites W945208301 @default.
• W2159841299 doi "https://doi.org/10.1016/j.ophtha.2006.02.027" @default.
• W2159841299 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16647134" @default.
• W2159841299 hasPublicationYear "2006" @default.
• W2159841299 type Work @default.
• W2159841299 sameAs 2159841299 @default.
• W2159841299 citedByCount "226" @default.
• W2159841299 countsByYear W21598412992012 @default.
• W2159841299 countsByYear W21598412992013 @default.
• W2159841299 countsByYear W21598412992014 @default.
• W2159841299 countsByYear W21598412992015 @default.
• W2159841299 countsByYear W21598412992016 @default.
• W2159841299 countsByYear W21598412992017 @default.
• W2159841299 countsByYear W21598412992018 @default.
• W2159841299 countsByYear W21598412992019 @default.
• W2159841299 countsByYear W21598412992020 @default.
• W2159841299 countsByYear W21598412992021 @default.
• W2159841299 countsByYear W21598412992022 @default.
• W2159841299 countsByYear W21598412992023 @default.
• W2159841299 crossrefType "journal-article" @default.
• W2159841299 hasAuthorship W2159841299A5019280205 @default.
• W2159841299 hasConcept C118487528 @default.
• W2159841299 hasConcept C126322002 @default.
• W2159841299 hasConcept C141071460 @default.
• W2159841299 hasConcept C168563851 @default.
• W2159841299 hasConcept C197934379 @default.
• W2159841299 hasConcept C2776403814 @default.
• W2159841299 hasConcept C2776694085 @default.
• W2159841299 hasConcept C2777512022 @default.
• W2159841299 hasConcept C2777802072 @default.
• W2159841299 hasConcept C2781100027 @default.
• W2159841299 hasConcept C2781156865 @default.
• W2159841299 hasConcept C2781359195 @default.
• W2159841299 hasConcept C71924100 @default.
• W2159841299 hasConceptScore W2159841299C118487528 @default.
• W2159841299 hasConceptScore W2159841299C126322002 @default.
• W2159841299 hasConceptScore W2159841299C141071460 @default.
• W2159841299 hasConceptScore W2159841299C168563851 @default.
• W2159841299 hasConceptScore W2159841299C197934379 @default.
• W2159841299 hasConceptScore W2159841299C2776403814 @default.
• W2159841299 hasConceptScore W2159841299C2776694085 @default.
• W2159841299 hasConceptScore W2159841299C2777512022 @default.
• W2159841299 hasConceptScore W2159841299C2777802072 @default.
• W2159841299 hasConceptScore W2159841299C2781100027 @default.
• W2159841299 hasConceptScore W2159841299C2781156865 @default.
• W2159841299 hasConceptScore W2159841299C2781359195 @default.
• W2159841299 hasConceptScore W2159841299C71924100 @default.
• W2159841299 hasIssue "6" @default.
• W2159841299 hasLocation W21598412991 @default.
• W2159841299 hasLocation W21598412992 @default.
• W2159841299 hasOpenAccess W2159841299 @default.
• W2159841299 hasPrimaryLocation W21598412991 @default.
• W2159841299 hasRelatedWork W1993747607 @default.
• W2159841299 hasRelatedWork W1994011733 @default.
• W2159841299 hasRelatedWork W1995841770 @default.
• W2159841299 hasRelatedWork W2000402551 @default.
• W2159841299 hasRelatedWork W2049577742 @default.
• W2159841299 hasRelatedWork W2069411345 @default.
• W2159841299 hasRelatedWork W2108402300 @default.
• W2159841299 hasRelatedWork W2233259956 @default.
• W2159841299 hasRelatedWork W2396116581 @default.
• W2159841299 hasRelatedWork W2599281049 @default.
• W2159841299 hasVolume "113" @default.
• W2159841299 isParatext "false" @default.
• W2159841299 isRetracted "false" @default.
• W2159841299 magId "2159841299" @default.
• W2159841299 workType "article" @default.